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Abstract
Purpose Longitudinal analysis of health-related quality
of life (HRQoL) remains unstandardized and compromises
comparison of results between trials. In oncology, despite
available statistical approaches, results are poorly used to
change standards of care, mainly due to lack of standard-
ization and the ability to propose clinical meaningful
results. In this context, the time to deterioration (TTD) has
been proposed as a modality of longitudinal HRQoL ana-
lysis for cancer patients. As for tumor response and pro-
gression, we propose to develop RECIST criteria for
HRQoL.
Methods Several definitions of TTD are investigated in
this paper. We applied this approach in early breast cancer
and metastatic pancreatic cancer with a 5-point minimal
clinically important difference. In breast cancer, TTD was
defined as compared to the baseline score or to the best
previous score. In pancreatic cancer (arm 1: gemcitabine
with FOLFIRI.3, arm 2: gemcitabine alone), the time until
definitive deterioration (TUDD) was investigated with or
without death as event.
Results In the breast cancer study, 381 women were
included. The median TTD was influenced by the choice of
the reference score. In pancreatic cancer study, 98 patients
were enrolled. Patients in Arm 1 presented longer TUDD
than those in Arm 2 for most of HRQoL scores. Results of
TUDD were slightly different according to the definition of
deterioration applied.
Conclusion Currently, the international ARCAD group
supports the idea of developing RECIST for HRQoL in
pancreatic and colorectal cancer with liver metastasis, with
a view to using HRQoL as a co-primary endpoint along
with a tumor parameter.
Keywords Health-related quality of life  Clinical
trials  Oncology  Longitudinal analysis  Time to
deterioration
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EORTC European Organisation for Research and
Treatment of Cancer
HR Hazard ratio
HRQoL Health-related quality of life
GLMM General linear mixed model
IRT Item response theory




TTD Time to deterioration
TUDD Time until definitive deterioration
Introduction
Although overall survival (OS) is still considered as the
‘‘gold standard’’ for primary endpoints in many oncology
studies, most clinical trials now integrate health-related
quality of life (HRQoL) as one of the major endpoints to
investigate the clinical benefit of new therapeutic strategies
for the patient. HRQoL is considered as a second primary
endpoint by the American Society of Clinical Oncology
and the Food and Drug Administration if no effect of
treatment on OS is observed [1–3]. Moreover, since many
trials in oncology use so-called surrogate endpoints for OS
focusing on tumor parameters, it is of major importance to
assess HRQoL in order to characterize the clinical benefit
for patients.
Despite this opportunity to achieve comprehensive
assessment of HRQoL to support ‘‘evidence-based medi-
cine’’ in oncology, the longitudinal analysis of HRQoL
remains unstandardized. This compromises the comparison
of results between trials. Moreover, longitudinal results
should translate findings into information that decision-
makers find understandable and compelling. However,
despite the many sophisticated statistical approaches
available, results remain underutilized in clinical practice,
especially due to a lack of standardization and the inability
to propose clinically meaningful results.
Analyses also have to deal with another limiting factor,
namely missing data. Patients may not complete the entire
HRQoL questionnaire at all planned measurement times.
Moreover, patients may drop out before the end of the
study, generally due to a deterioration of their health status,
or death, as in the palliative setting. Missing data can bias
the analysis and interpretation of the results if they depend
on the patient’s health status [4–6]. Therefore, there is a
need to develop statistical methods that can handle missing
data [7–12].
Another challenge of longitudinal HRQoL analysis is to
take into account the potential occurrence of a response
shift (RS) effect. Indeed, self-assessment of HRQoL is
dependent on the patient’s internal standards and the defi-
nition of HRQoL used [13–15]. Since patients can adapt to
disease and the treatment toxicities, their health and
HRQoL expectations may also change over time. These
changes result in an RS effect [16]. Sprangers and Sch-
wartz defined RS as ‘‘a change in the meaning of one’s
self-evaluation of a target construct as a result of the fol-
lowing: (a) a change in the respondent’s internal standards
of measurement (i.e., scale recalibration); (b) a change in
the respondent’s values (i.e., the importance of component
domains constituting the target construct); or (c) a redefi-
nition of the target construct (i.e., reconceptualization)’’
[17]. Thus, the choice of the reference score to qualify a
change such as deterioration is a major concern.
Several methods are used to analyze longitudinal
HRQoL data [18–20]. The most widely used is the general
linear mixed model (GLMM) [18, 21–23], which is rec-
ommended in longitudinal studies with a limited number of
follow-up [24]. This method is only adapted when HRQoL
assessments are widely spaced and with little amplitude
within patients. GLMM can handle the missing data pro-
files by applying a pattern mixture model [10, 25]. How-
ever, these sub-models are rarely applied, mainly because
of the complexity of the pattern construction [10, 25–27].
Furthermore, GLMM does not deal with the occurrence of
a RS effect.
In the last few years, researchers have started to use
models of modern item response theory (IRT) to analyze
longitudinal HRQoL data [28]. In contrast to the GLMM,
the link between the observed score and the latent trait
(e.g., HRQoL) is not linear but logistic. However, these
models are rarely used to analyze longitudinal HRQoL
data, mainly due to their complexity [29].
Also in recent years, time-to-event models such as the
time-to-HRQoL score deterioration (TTD) have been pro-
posed as an approach to the analysis of longitudinal
HRQoL in oncology [30, 31]. Both GLMM and TTD rely
on the definition of the minimal clinically important dif-
ference (MCID) in order to be effective from a clinical
point of view. The measure of TTD might be more familiar
to clinicians because it is based on Kaplan–Meier survival
curves and hazard ratios (HR). As for GLMM, TTD can
deal with missing data by making underlying assumptions
about whether the missing data reflect a deterioration of the
patient’s health status or not. Contrary to GLMM, the TTD
method can take into account the occurrence of the RS
recalibration component by choosing different reference
scores to qualify the deterioration.
TTD cannot be considered as an exclusive method, since
the GLMM approach measures different concepts and
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proposes complementary ways of summarizing HRQoL
data. However, if few HRQoL assessments are performed
and the interval time between two consecutive assessments
is long, then GLMM may be more relevant than the TTD
approach. In other cases, the TTD approach may be more
suitable than GLMM.
Regarding the TTD approach, the choice of event defi-
nition is essential, because it may lead to different results.
However, there are currently no recommendations or
consensus in this regard, with the result that TTD reflects
heterogeneity.
Thus, there is a clear need to investigate and validate
several definitions of TTD depending on the following: the
cancer context (adjuvant, advanced), reference score, event
definitions, MCID, and censoring rules. As for tumor
response and progression, one proposition could be to
develop ‘‘RECIST’’ criteria (‘‘Response Evaluation Crite-
ria In Solid Tumors’’) for HRQoL. This would allow
standardization of longitudinal HRQoL analysis using the
TTD method, according to the therapeutic situation and the
cancer site. Accordingly, several definitions of TTD were
investigated and are presented in this paper. We next
propose recommendations for the choice of the definition
depending on the therapeutic situation. Finally, we report
results observed using the TTD approach in early breast
cancer and metastatic pancreatic cancer.
Methods
Time to deterioration definitions
We propose several definitions of TTD in a HRQoL score
according to the therapeutic situation and cancer site.
Events can be defined in relation to a reference score,
MCID, and missing scores, including death or not. These
definitions are summarized in Table 1.
1) Core definitions with respect to the MCID
The most intuitive definition for TTD is the time from
inclusion–randomization in the study to
• a first deterioration of at least one MCID unit as
compared to the baseline score [31] (Fig. 1a).
• Patients with no deterioration before their dropout are
censored at the time of the last follow-up or the last
HRQoL assessment.
This definition corresponds to definition TTD#1 in
Table 1.
According to the scoring algorithm of the HRQoL
dimension, the deterioration corresponds to an increase or
decrease in at least one MCID unit of the score as
compared to the baseline score. The MCID may vary
depending on the instruments and cancer sites under
consideration.
The deterioration observed can be definitive or not. In
the palliative setting, Bonnetain et al. have previously
defined the time until definitive HRQoL score deterioration
(TUDD) as the time from inclusion in the study to a first
deterioration of at least one MCID unit as compared to the
baseline score:
• with no further improvement of more than one MCID
unit as compared to the baseline score (Fig. 1b).
• or if the patient dropped out after deterioration,
resulting in missing data.
This corresponds to the definition TUDD#1 in Table 1.
An alternative for defining TUDD is to consider that the
first deterioration of at least one MCID unit observed at
time T is definitive:
• if the deterioration of at least one MCID unit as
compared to the baseline score is also observed at all
time points after time T (Fig. 1c).
• or if the patient dropped out after deterioration,
resulting in missing data.
This second definition of TUDD corresponds to defini-
tion TUDD#5 of Table 1.
2) Alternatives for defining the reference score
The concept of deterioration requires a reference score
relative to which the deterioration may be quantified. In the
definitions described here, the reference score is the base-
line score. However, the reference score could also be
defined in other ways. For example,
• the best previous HRQoL score. Figure 1d illustrates
the TTD with a 10-point MCID as compared to the best
previous HRQoL score for one patient (TTD#5 in
Table 1) or
• the previous HRQoL score. Figure 1e illustrates the
TTD with a 10-point MCID for one patient with the
previous score (i.e., ‘‘immediately preceding score’’) as
the reference score (TTD#9 in Table 1).
Moreover, for definitive deterioration, the deterioration
observed at time T can be considered definitive:
• as compared to the reference score (baseline score,
previous score, or best previous score) or
• as compared to the score qualifying the deterioration
(i.e., the score obtained at time T). In that case, the
score qualifying the deterioration at time T becomes the
reference score (TUDD#9). Figure 1f. illustrates the
TUDD as compared to the baseline score with no
Qual Life Res (2015) 24:5–18 7
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further improvement as compared to the score qualify-
ing the deterioration for one patient.
3) Missing data issues
Intermittent missing data are ignored in the TTD
approach, which goes on the assumption that HRQoL
level remains unchanged since the last available HRQoL
assessment. Moreover, patients with no baseline HRQoL
score or with no follow-up score are usually excluded
from longitudinal analysis. However, these patients can
be included in the analysis and censored at baseline or
just after baseline. Depending on the therapeutic situa-
tion, sensitivity analysis can be performed considering
these patients to be deteriorating since baseline. For
example, definition TUDD#2 in Table 1 corresponds to
TUDD as compared to the baseline score, according to
the definition of Bonnetain et al., including patients with
no baseline HRQoL score or with no follow-up score as
events.
4) Death as an event
All-cause death can be considered as an event if the
patient did not experience deterioration before death. These
supplementary events (death, no follow-up) will be
addressed in the case of TUDD. In this way, TUDD or
death could be redefined as ‘‘HRQoL deterioration-free
survival.’’ For example, definition TUDD#3 in Table 1
corresponds to TUDD as compared to the baseline score
according to the definition of Bonnetain et al., or death.
5) Response shift issue
Patients’ internal standards can change over time,
reflecting the recalibration component of RS. An alterna-
tive way to take into account the occurrence of the recal-
ibration component of RS could be to consider the
reference score as the best previous HRQoL score, or the
previous (immediately preceding) HRQoL score but not
the baseline sore. The value of these scores can change
over time according to the patient’s experience of treatment
and disease course.
6) Multidimensional definition
We can study the deterioration of one given HRQoL
score, or the deterioration of at least one HRQoL dimen-
sion among the set of all dimensions. For example, we can
study deterioration of at least one dimension of a multidi-
mensional questionnaire. In the case of a multidimensional
definition, the event time corresponds to the first deterio-
ration observed, irrespective of which HRQoL score is
affected. In this situation, competitive risks should be taken
into account. This multidimensional definition has the
advantage of increasing the statistical power and may be
relevant if the treatment is expected to have a similar effect
on all the HRQoL dimensions retained.
As TTD analyses count as survival analyses, the TTD
estimation can be calculated using the Kaplan–Meier or
actuarial method and described using median and 95 % con-
fidence interval (CI). The Kaplan–Meier survival curve is
defined as the probability of surviving in a given length of time
while considering time in many small intervals. This method
is based on the intuitive idea that being alive at time T natu-
rally requires the subject to be alive just before time T, and not
to die at time T [32]. Contrary to the Kaplan–Meier method, in
the actuarial method, probabilities are estimated for fixed time
intervals, not determined by the date of observed death. Both
methods can handle the presence of censored data, i.e.,
patients are still alive at the end of the study.
In time to deterioration (TTD) analyses, the event is
‘‘the HRQoL score deterioration.’’ The Kaplan–Meier
estimation is given by the following formula:
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A cross (X) indicates the retained definition and the corresponding events
a MCID? deterioration with no further improvement as compared to the reference score (definition of Bonnetain et al.)
b MCID- definitive deterioration if deterioration observed at all time points following the initial deterioration
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Ti-1, mi is the number of events observed at time Ti, i.e.,
the number of patients experiencing a HRQoL score
deterioration at time Ti, and ci is the number of censored
patients at time Ti, i.e., the number of patients who dropped

































































f TUDD as compared to the baseline score
deterioration observed at all times following  TUDD as compared to the baseline score with no 
further impro as compared to the score
 qualifying the deterioration
 TUDD as compared to the baseline score 
with no further impro as compared to the
baseline score  
e
time of the deterioration
Fig. 1 Illustration of time to deterioration (Td) using different
definitions with a 10-point MCID for one patient and for a health-
related quality of life score (QoL) in which a deterioration
corresponds to a decrease in the score. The solid line corresponds
to the value of the reference score at time Td. The dashed line
corresponds to the threshold to observe deterioration as compared to
the reference score at time Td. The dotted line corresponds to the
threshold to observe a definitive deterioration as compared to the
reference score at time Td
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TTD can then be compared according to treatment arm
using the log-rank test and univariate Cox analyses to pro-
duce a HR with 95 % CI. Multivariate Cox regression can be
applied to identify independent factors associated with TTD.
In Fig. 2, we propose a decision-making flowchart. In the
adjuvant setting, we recommend using the TTD; and in the
advanced or metastatic setting, we recommend using the
TUDD, with or without death from all causes as an event.
Indeed, it is intuitive that in the adjuvant setting, deteriora-
tion is expected not to be definitive, because the patient could
conceivably survive the cancer. Moreover, cancer survivors
can experience an improvement of their HRQoL. In contrast,
in the advanced or metastatic setting, a definitive deteriora-
tion is more relevant, reflecting the deterioration of the
patient’s health status, which is stable over time. Further-
more, the time between deterioration and death is often short
for these patients [30]. The definition of the deterioration is
based on both the threshold for the MCID, and the definition
chosen for the reference score. Thus, if no RS effect occurs,
the baseline score can be kept as the reference score in the
TTD analysis. If a RS is likely to occur, we recommend using
the best previous score or the previous score as the reference
score in the TTD analysis.
Health-related quality of life studies
In this section, we report TTD analyses performed in two
studies as an illustration, namely early breast cancer and
metastatic pancreatic cancer. In the breast cancer study,
since it is an adjuvant setting, we retained the TTD
approach and studied the impact of RS on TTD using
changing score as the reference score, i.e., the best previous
score. In the metastatic pancreatic cancer study, as it is a
metastatic setting, we retained the TUDD approach,
integrating death (or not) as event. We also took into
account informative missing data.
Time to deterioration in early breast cancer
A prospective, multicenter, randomized, cohort study
including all women hospitalized for the diagnosis or
treatment of first primary breast cancer or for a suspicion
of breast cancer was performed in French hospitals
between February 2006 and February 2008. All partici-
pants gave written informed consent, and the local ethics
committee approved the study protocol. The complete
design of this study has previously been described else-
where [33].
HRQoL was evaluated using the EORTC cancer-spe-
cific questionnaire QLQ-C30 [34] and its breast cancer
module QLQ-BR23 [35]. These were administered at
inclusion, at discharge following initial hospitalization, as
well as at three and 6 months after inclusion. The QLQ-
C30 and its breast cancer module BR23 are validated tools
to assess HRQoL in cancer, specifically in breast cancer
[34, 35].
The QLQ-C30 includes 30 items and measures five
functional scales (physical, role, emotional, cognitive, and
social functioning), global health status (GHS), financial
difficulties, and eight symptom scales (fatigue, nausea and
vomiting, pain, dyspnea, insomnia, appetite loss, consti-
pation, and diarrhea) [34].
The BR23 module includes 23 items that generate four
functional scales (body image, sexual functioning, sexual
enjoyment, and future perspective) and four symptom
scales (systemic therapy side effects, breast symptoms, arm
symptoms, and upset caused by hair loss) [35].
Fig. 2 Decision-making flowchart according to the therapeutic situation
Qual Life Res (2015) 24:5–18 11
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The occurrence of a RS effect has already been dem-
onstrated in early breast cancer patients [33, 36] and par-
ticularly in this study [31, 33]. Thus, two definitions of
TTD were investigated using a 5-point MCID: The first
definition was TTD with the baseline score as the reference
score [31]. The second was TTD with the best previous
score as the reference score. Patients with at least one
HRQoL score were included in the TTD analysis. Patients
with no follow-up HRQoL score were censored just after
baseline. Patients with no baseline score were censored at
baseline.
TTD curves were calculated using the Kaplan–Meier
estimation and described using median and 95 % CI.
Time until definitive deterioration in metastatic pancreatic
cancer
This study was a multicenter, randomized, open phase II
trial conducted in 11 French centers between October 2007
and May 2011. Randomization 1:1 was done using the
minimization technique with stratification according to
center, performance status (0 vs. 1), and the number of
metastatic sites (one vs. more than one).
Inclusion criteria were as follows: histologically or
cytologically proven metastatic pancreatic adenocarci-
noma, no previous chemotherapy, no previous radiother-
apy, and WHO performance status \2.
Exclusion criteria were bile duct adenocarcinoma,
ampulloma, and history of another major cancer.
All patients were fully informed of the study and provided
written informed consent. The protocol was approved by the
ethics committee.
Patients were randomly assigned to receive alternately
FOLFIRI 3 every 14 days for 2 months (i.e., 4 courses per
cycle), followed by gemcitabine, 6 courses at days 1, 8, 15,
29, 36, and 43 per cycle (Arm 1) or gemcitabine alone
(Arm 2). FOLFIRI 3 is a chemotherapeutic regimen com-
bining 5-fluorouracil, folinic acid, and irinotecan.
HRQoL was evaluated using the QLQ-C30 question-
naire [34] at inclusion and every 2 months until the end of
the study or death.
The TUDD was defined as the TUDD with a 5-point
MCID as compared to the baseline score, with no further
improvement of more than 5 points [30]. Patients with at
least one HRQoL score were included in the TUDD analysis.
Patients with no baseline score were censored at baseline.
Patients with no follow-up measures were censored just after
baseline. Sensitivity analyses were conducted, first consid-
ering death as an event and then simultaneously considering
death and no follow-up as events. TUDD analyses including
death as an event are referred to ‘‘HRQoL deterioration-free
survival’’ analyses.
TUDD curves were calculated using the Kaplan–Meier
method and described using median and 95 % CI. TUDD
was compared between treatment arms using the log-rank
test and univariate HR with 95 % CI.
For both studies, variables collected at baseline are
described as means and standard deviations (SD) for con-
tinuous variables and number (percentage) for qualitative
variables. The percentage of missing data is also provided.
The number of HRQoL questionnaires completed at each
measurement time is reported. Scores were generated
according to the EORTC scoring manual [37]. These scores
vary from 0 (worst) to 100 (best) for the functional
dimensions and GHS, and from 0 (best) to 100 (worst) for
the symptom dimensions.
All analyses were performed with R software [38].
Results
Breast cancer
Between February 2006 and February 2008, 381 patients
were included in the four participating centers. Mean age
was 58.4 (SD = 11) years. Complete clinical and patho-
logic characteristics of the population are given in sup-
plementary Table A.
At baseline, 359 (94 %) patients had at least one
HRQoL score, 343 (90 %) at discharge following initial
hospitalization, 340 (89 %) at three months, and 321
(84 %) at 6 months.
Results of the TTD analyses are summarized in
Table 2.Among the 377 patients included with at least one
cognitive functioning score, 160 and 197 patients presented
deterioration of cognitive function as compared to the
baseline score and the best previous score, respectively.
The median TTD decreased from 6.1 months [5.4–NA]
when baseline was the reference score to 3.5 [3.2–6.0]
when the reference was the best previous score (Fig. 3a).
Among the 375 patients included with at least one breast
symptoms score, 228 and 284 patients presented breast
symptom deterioration as compared to the baseline score
and the best previous score, respectively. The median TTD
increased from 0.2 months [0.2–2.8] when recalibration
was not taken into account to 2.8 [2.8–3.0] when it was
taken into account (Fig. 3b).
Among the 375 patients included with at least one arm
symptoms score, 214 and 247 patients presented arm
symptoms deterioration as compared to the baseline score
and to the best previous score, respectively. The median
TTD increased from 2.9 months [0.4–3.1] when recali-
bration was not taken into account to 6.0 [3.6–6.0] when it
was.
12 Qual Life Res (2015) 24:5–18
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Pancreatic cancer
Between October 2007 and May 2011, 98 patients were
enrolled in 10 French centers. Mean age was 62 years
(SD = 8.4). The baseline characteristics of the patients are
summarized in supplementary Table B.
At baseline, 34 patients (69.4 %) completed the QLQ-
C30 questionnaire in Arm 1 (gemcitabine ? FOLFIRI 3)
and 30 patients (61.2 %) in Arm 2 (gemcitabine alone)
(supplementary Table C).
The TUDD as compared to the baseline score with a
5-point MCID or death was retained for the primary ana-
lysis. The Kaplan–Meier curves showing TUDD for the
physical functioning and pain scales are shown in Fig. 4.
Patients in Arm 1 (gemcitabine ? FOLFIRI 3) seem to
present a longer TUDD than those in Arm 2 (gemcitabine
alone) for each HRQoL score (Table 3).
Whatever the definition applied, patients in Arm 1 (gem-
citabine ? FOLFIRI 3) presented a longer TUDD of insom-
nia than those of Arm 2 (gemcitabine alone) with HR \ 1.
Regarding TUDD definitions integrating death or not,
patients in Arm 1 (gemcitabine ? FOLFIRI 3) presented a
longer TUDD than those in Arm 2 (gemcitabine alone) for
physical functioning, but this trend was no longer signifi-
cant when we considered patients with no follow-up as
having deteriorated at baseline.
Discussion
Definitions of deterioration applied in this paper, such as
TTD compared to baseline score in breast cancer, and
TUDD according to the definition of Bonnetain et al. in the
pancreatic cancer study, have also been applied in other
studies [39, 40]. This demonstrates the didactic nature of
this approach.
Different definitions of TTD have been proposed and
investigated in this paper. According to the definition
applied, results can change and this precludes
Table 2 Results of the Kaplan–Meier estimation of the time to deterioration (TTD) for each QLQ-C30 score and QLQ-BR23 score with the
baseline score or the best previous score as the reference score regarding breast cancer study (study #1)
TTD baseline score TTD best previous score
n (events) Median in months
(95 % CI)
n (events) Median in months
(95 % CI)
QLQ-C30
Global health status 376 (224) 3.0 (2.8–3.0) 376 (263) 3.0 (2.9–3.0)
Physical functioning 376 (255) 0.2 (0.2–2.8) 376 (290) 0.4 (0.2–2.9)
Role functioning 375 (235) 3.0 (3.0–3.0) 375 (262) 3.0 (3.0–3.0)
Emotional functioning 377 (153) 6.1 (6.0–NA) 377 (232) 5.6 (3.2–5.9)
Social functioning 377 (193) 3.1 (3.0–5.9) 377 (221) 3.1 (3.0–5.4)
Cognitive functioning 377 (160) 6.1 (5.4–NA) 377 (197) 3.5 (3.2–6.0)
Fatigue 374 (248) 2.7 (0.2–3.0) 374 (282) 2.9 (0.4–3.0)
Pain 377 (234) 3.0 (0.6–3.0) 377 (268) 4.0 (2.8–3.0)
Nausea and vomiting 375 (123) 7.0 (6.1–NA) 375 (139) 7.0 (6.1–NA)
Dyspnea 375 (126) 6.2 (6.1–NA) 375 (164) 6.1 (6.0–6.2)
Insomnia 374 (141) 6.1 (6.0–NA) 374 (194) 6.0 (5.7–6.0)
Appetite loss 375 (106) NA (6.3–NA) 375 (124) 6.5 (6.3–NA)
Constipation 377 (147) 6.2 (6.0–NA) 377 (173) 6.0 (5.9–6.4)
Diarrhea 375 (59) NA (6.5–NA) 375 (81) 6.5 (6.4–NA)
Financial difficulties 376 (70) NA (6.4–NA) 376 (78) NA (6.4–NA)
QLQ-BR23
Body image 376 (207) 3.0 (3.0–3.1) 376 (236) 3.0 (3.0–3.2)
Sexual functioning 354 (71) 6.4 (6.3–NA) 354 (118) 6.2 (6.1–6.4)
Sexual enjoyment 224 (21) 7.4 (6.4–NA) 224 (45) 6.4 (6.2–NA)
Future perspective 375 (90) 7.0 (6.6–NA) 375 (165) 6.1 (6.0–6.1)
Systemic therapy side effects 376 (194) 3.1 (3.0–3.4) 375 (233) 3.1 (3.0–3.2)
Breast symptoms 375 (228) 0.2 (0.2–2.8) 375 (284) 3.0 (2.8–3.0)
Arm symptoms 375 (214) 2.9 (0.4–3.1) 375 (247) 6.0 (3.6–6.0)
Upset by hair loss 194 (16) 3.3 (3.1–NA) 194 (38) 6.3 (6.2–NA)
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comparison of results between oncology clinical trials.
The multiplicity of possible event definitions is a limi-
tation of TTD analysis, as it can change the conclusions
drawn from the same study. For this reason, it is
essential to achieve a consensus. Moreover, if interval
estimation of survival analysis is used, the ‘‘real’’ dete-
rioration time is unknown, and as a result, the TTD will
be overestimated, but biological markers such as pro-
gression-free survival also use this estimation method.
An alternative is under investigation, for example, with
patients completing the HRQoL questionnaire when they
perceive a change.
In this paper, we report the results of TTD analyses
according to different therapeutic situations (adjuvant or
metastatic) and cancer sites (breast and pancreatic cancers).
The impact of some challenges of longitudinal HRQoL
analysis on TTD is also studied, namely occurrence of RS in
breast cancer study and missing data in pancreatic cancer.
We adjusted the definition of deterioration and the choice of
the reference score according to the problem being studied.
In the breast cancer study, we noted that the choice of
the reference score impacted on the median TTD. When
the best previous score was used as the reference, rather
than the baseline score, the median TTD of cognitive
functioning decreased while that of the breast and arm
symptoms increased. The median TTD is sensitive to the
choice of reference score. One limitation of this study is the
number of HRQoL assessments. Only four assessments of
HRQoL during the study were planned. In the pancreatic
cancer study, results were slightly different according to
the definition applied. Regarding TUDD definitions
integrating death or not, patients in Arm 1 (gemcita-
bine ? FOLFIRI 3) presented a significantly longer TUDD
than those of Arm 2 (gemcitabine alone) for physical
functioning, but this trend was no longer significant when
we considered patients with no follow-up as deteriorated at
baseline.
In early breast cancer (study #1), the TTD definition
applied, using the best previous score as the reference, has
the advantage of taking into account the occurrence of the
recalibration component of RS. The occurrence of short-
term recalibration in this study was previously demon-
strated [33]; thus, we had to adjust the method of longi-
tudinal analysis according to the change in the patients’
internal standards. Different methods of assessing RS exist
[41–43]. However, the challenge is to take into account the
occurrence of the RS effect in longitudinal analysis in order
to estimate the true change. The ‘‘then-test’’ method, which
assesses patients’ pretest HRQoL levels retrospectively, is
the most popular method to assess RS [44]. However, this
method is time-consuming, and given its retrospective
nature, the then-test is susceptible to recall bias [45]. The
TTD approach has the advantage of taking recalibration
into account without additional questionnaires, by using
changing scores as a reference. Currently, few longitudinal
methods can integrate the occurrence of a RS effect.
Structural equation modeling can separate true change
from RS effect [42, 46]. However, due to the complexity of
this method, it is difficult to propose a simple interpretation
of these models to clinicians.
The TTD approach is suitable for different therapeutic
situations. Indeed, using the pancreatic cancer study, we
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Fig. 3 Time to HRQoL score
deterioration curves with a
5-point MCID for breast cancer
(study #1) with baseline score or
best previous score as the
reference score for cognitive
functioning (CF) (panel A), and
breast symptoms (BS) (panel B)
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integrated the metastatic component as a definitive deteri-
oration with death as an event.
Many definitions of deterioration have been proposed in
this paper. The choice of the event definition is essential,
because it may induce different results. However, there is
currently no recommendation or consensus on this point.
Consequently, TTD reflects heterogeneity. In the adjuvant
setting, we thus recommend using the TTD; and in the
advanced or metastatic setting, we recommend using the
TUDD with or without death as an event. The baseline
score could be considered as the reference score if there is
no evidence of a RS effect. If a RS is likely to occur, we
recommend using the best previous score or the previous
score as the reference score in the TTD analysis.
As in other statistical methods for longitudinal analysis,
the TTD approach can handle the occurrence of missing
data by making some underlying assumptions, either by
considering that the HRQoL level is constant for inter-
mittent missing data, or by considering the missing
HRQoL score as revealing the deterioration of the
patient’s health status. Few statistical methods handle
missing data in longitudinal studies of HRQoL, and these
methods are rarely applied due to their complexity. Pattern
mixture models have been proposed to analyze longitu-
dinal HRQoL with missing data [10, 25]. However, the
number of patterns may be considerable and makes diffi-
cult the estimation of the model parameters for each plan.
In this way, the TTD approach seems to be more appro-
priate than GLMM with pattern mixture for studies with
many HRQoL assessments, although these two approaches
measure different concepts, and thus, TTD cannot be a
substitute for GLMM. In the pancreatic cancer study, we
considered patients with no follow-up measure as having
deteriorated since baseline. Further research is needed to
take into account missing data profiles in TTD analyses.
We are currently developing a method to use in con-
junction with TTD to take into account missing not-at-
random data using a method derived from a propensity
score.
Results of TTD analysis could be more suitable than
GLMM for clinicians, who are familiar with survival
analysis, with HR, and log-rank test. However, both
GLMM and TTD rely on the definition of MCID to be
effective from a clinical point of view. Thus, these methods
share the same limitation deriving from the lack of con-
sensus around the MCID definition. Longitudinal results
should have the ability to translate findings into informa-
tion that decision-makers find understandable and com-
pelling. At this time, despite available statistical
approaches, results are poorly utilized to change standards
of care, mainly due to the lack of standardization and the
failure to propose clinical meaningful results.
An ongoing project aims to compare TTD and GLMM
using a simulation study [47, 48]. The objective of this
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Fig. 4 Kaplan–Meier survival curves for the time until definitive deterioration or death for the pancreatic cancer study (study #2)
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project is to propose a standard for longitudinal HRQoL
analysis in oncology according to therapeutic situations
and cancer sites.
To reach the goal of standardized longitudinal analysis
methods for HRQoL, we purport that RECIST criteria for
HRQoL regarding TTD are required. We propose the first
components of the RECIST criteria here: (1) TTD and
TUDD in the adjuvant and advanced/metastatic settings,
respectively, with baseline score as a reference, and (2)
with the best previous score or the previous score as a
reference if RS effect is likely to occur. Further work is
needed to achieve a consensus for each cancer setting and
tumor site. Moreover, additional investigations are still
required regarding the MCID determination to achieve
consensus on a definition for MCID.
The TTD approach is already implemented in R soft-
ware (submitted soon) to allow wider dissemination of
these approaches and help move toward the goal of
standardization.
At this time, the international ARCAD group (‘‘Aide et
Recherche en Cance´rologie Digestive’’) supports the idea of
developing RECIST criteria for HRQoL in colorectal cancer
with liver metastasis and pancreatic cancer. Subsequently,
HRQoL could then be considered as a co-primary endpoint
along with a tumor parameters such as progression-free sur-
vival [49]. Future research is warranted on this subject [50].
For example, calculating the number of subjects required for
a study with co-primary endpoints is still ongoing.
Conclusion
The TTD is a didactic and promising approach that we
recommend for the longitudinal analysis of HRQoL in
oncology, especially because of its capacity to handle RS
and to provide results in a format that is familiar to
clinicians.
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